Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response.
D000328:Adult; D000917:Antibody Formation; D001500:BCG Vaccine; D002175:Candida / Q000276:immunology; D003165:Complement System Proteins / Q000032:analysis; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000175:diagnosis; D007111:Immunity, Cellular; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000276:immunology*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000628:therapy; D012878:Skin Neoplasms / Q000276:immunology*; D012882:Skin Tests; D013936:Thymidine / Q000378:metabolism; D014316:Tritium; D014374:Tuberculin Test
D001500:BCG Vaccine; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D037102:Lectins; D014316:Tritium; D003165:Complement System Proteins; D013936:Thymidine